Baseline characteristics of the subjects
| Placebo (n=22) | DRCFI (n=20) | |
|---|---|---|
| Age (years)* | 59.5 (13.2) | 70 (5.6) |
| Female—number (%) | 13 (59.1) | 10 (50) |
| FEV1 (l) | 1.47 (0.73) | 1.57 (0.77) |
| FEV1 per cent predicted (%) | 53.1 (22.7) | 60.7 (24.1) |
| Sputum Pseudomonas aeruginosa bacterial density (log10 CFU/g) | 5.9 (2.7) | 6.5 (2.3) |
| Other sputum organisms present in >1 subject† | Klebsiella spp. Ochrobactrum anthropi | Klebsiella spp. |
| Comorbidities—n | ||
| Ischaemic heart disease | 9 | 10 |
| Hypertension | 6 | 9 |
| Diabetes mellitus | 2 | 0 |
| Cerebrovascular disease | 1 | 0 |
| Medications—n | ||
| Maintenance oral macrolides | 4 | 5 |
| Inhaled corticosteroids | 4 | 6 |
| Combination inhalers (ICS/LABA) | 9 | 11 |
| Inhaled LABA | 2 | 2 |
| Inhaled SABA | 13 | 10 |
| Inhaled LA anticholinergic | 5 | 7 |
| Inhaled SA anticholinergic | 4 | 1 |
| Prednisone | 1 | 1 |
| Inhaled mannitol | 2 | 2 |
| Prior smokers—n | 0 | 1 |
Values are mean (SD) except where otherwise indicated.
*p<0.01 for the comparison between groups for age; there were no significant differences between groups for other variables.
†n=2 for each of these organisms.
CFU, colony forming unit; DRCFI, dual release ciprofloxacin for inhalation, FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids, LA, long-acting; LABA, long-acting β-agonists, SA, short-acting; SABA, short-acting β-agonists.